American Society of Hirudotherapy

Reversal of anticoagulant effects in patients with intracerebral hemorrhage

Review published in Current neurology and neuroscience reports (2015)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewClinical LiteratureDrug DevelopmentYates et al. · Current neurology and neuroscience reports, 2015

Abstract

Anticoagulant therapies are increasingly being used for the treatment and prevention of thromboembolic diseases. A growing incidence of anticoagulant-associated intracranial hemorrhage (AICH) has accompanied the rise in their use. Although the rate of intracerebral hemorrhage (ICH) in patients receiving anticoagulation therapies such as heparin and target-specific oral anticoagulants (TSOAs) is significantly lower than that of vitamin K antagonists (VKAs), the mortality rate remains high. TSOAs have only recently become available for use in clinical practice, and presently, there is a paucity of both clinical data and evidence-based guidelines to assist in the management of TSOA-associated intracerebral hemorrhage. In this article, we review current literature and provide physicians with diagnostic and therapeutic considerations for the management of AICH.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnimalsAnticoagulantsCerebral HemorrhageHumans

Summary

This review addresses anticoagulant-associated intracerebral hemorrhage: although hemorrhage rates are lower with heparin and target-specific oral anticoagulants than with vitamin K antagonists, mortality remains high, and the authors offer diagnostic and therapeutic considerations for management.

Context

This narrative review surveys the diagnosis and management of anticoagulant-associated intracranial hemorrhage (AICH), noting that while target-specific oral anticoagulants (TSOAs) and heparin carry a lower intracerebral-hemorrhage rate than vitamin K antagonists, mortality stays high and evidence-based reversal guidance for TSOA-associated bleeds remains sparse. It frames the clinical safety boundary around any anticoagulant strategy: the medicinal-leech secretome contributes potent direct thrombin inhibitors (hirudin) and other antithrombotics to the drug-discovery pipeline, so the same bleeding-management questions raised here apply whenever leech-derived anticoagulation is considered, and the recognized challenge of reversing these agents underscores why caution is warranted near the central nervous system. This is a review article summarizing other studies rather than original trial data, and it does not address hirudotherapy or leech-derived compounds directly; it is context for the anticoagulant-safety landscape, not evidence for clinical leech use.

Citation

Reference (Vancouver style)

Yates S, Sarode R. Reversal of anticoagulant effects in patients with intracerebral hemorrhage. Curr Neurol Neurosci Rep. 2015;15(1):504. doi:10.1007/s11910-014-0504-2. PMID: 25407132

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.